Safety and Efficacy of R-CMOP Versus R-CHOP in the Initial Treatment of Low-risk and Medium-risk Diffuse Large B-cell Lymphoma (DLBCL): a Randomized, Controlled, Open-label, Multicenter, Phase Ib/II Clinical Study
Status: Recruiting
Location: See all (10) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1/Phase 2
SUMMARY
This is a prospective, randomized, controlled, multicenter, phase II clinical trial to evaluate the efficacy and safety of R-CMOP versus R-CHOP in the initial treatment of low-risk and medium-risk diffuse large B-cell lymphoma (DLBCL).
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 80
Healthy Volunteers: f
View:
• Aged ≥18,≤80 years, both male and female.
• Pathologically confirmed DLBCL
• No prior treatment for DLBCL.
• There must be at least one measurable or evaluable lesion that meets the evaluation criteria for Lugano 2014 lymphoma.
• Eastern Cooperative Oncology Group (ECOG) performance status score of 0-
• Expected survival ≥3 months.
• International Prognostic Index (IPI) ≤ 2
• Sufficient bone marrow, liver, and kidney function.
Locations
Other Locations
China
Beijing Tongren Hospital
NOT_YET_RECRUITING
Beijing
Fujian Provincial Cancer Hospital
NOT_YET_RECRUITING
Fuzhou
Ganzhou Cancer Hospital
NOT_YET_RECRUITING
Ganzhou
The Affiliated Hospital of Guangdong Medical University
NOT_YET_RECRUITING
Guangzhou
The Fifth Affiliated Hospital of Guangzhou Medical University.
RECRUITING
Guangzhou
Guangxi Zhuang Autonomous Region Cancer Hospital
NOT_YET_RECRUITING
Guilin
Gansu Provincial Cancer Hospital
NOT_YET_RECRUITING
Lanzhou
Jiangxi Provincial Cancer Hospital
NOT_YET_RECRUITING
Nanchang
Shenzhen People's Hospital
NOT_YET_RECRUITING
Shenzhen
The Fifth Affiliated Hospital of Sun Yat-sen University
RECRUITING
Zhuhai
Contact Information
Primary
Qingqing Cai, MD. PhD.
caiqq@sysucc.org.cn
0086-20-87342823
Time Frame
Start Date: 2025-01-10
Estimated Completion Date: 2028-11-30
Participants
Target number of participants: 112
Treatments
Experimental: Experimental group
R-CMOP group
Active_comparator: Control group
R-CHOP group
Related Therapeutic Areas
Sponsors
Leads: Sun Yat-sen University